Drugs / TROP2-CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05922930 | Oct 2023 → Oct 2027 | adenocarcinoma, malignant pancreatic neoplasm, ovarian cancer | M.D. Anderson Cancer Center | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TROP2-CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05922930 ↗ |
| Modality | Cell therapy | “TROP2-CAR/IL15-transduced CB-NK cells” NCT05922930 ↗ |
| Route | Other | “Given by IP (intraperitoneal)” NCT05922930 ↗ |